Latest Breaking News On - Srikala sridhar - Page 1 : comparemela.com

ESMO 2023: Current Peri-Operative Trial Designs and Endpoints: What Do They Mean?

ESMO 2023: Current Peri-Operative Trial Designs and Endpoints: What Do They Mean?
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

Comunidad autonoma de catalunaSrikala sridharPerioperative pembrolizumabUniversity of torontoEuropean society of medical oncologySociety of urologic oncologyDepartment of medicinePrincess margaret cancer centreMedical oncologyAnnual congressUrologic oncologyClinical fellowAdjuvant only pembrolizumabEarly stage nonSmall cell lung

Long-term Outcomes From JAVELIN Bladder 100 Solidify Maintenance Avelumab as SOC in Metastatic Urothelial Carcinoma

A long-term post-hoc analysis from the JAVELIN Bladder 100 trial demonstrated that first-line maintenance avelumab elicited similar overall survival and progression-free survival benefits vs best supportive care alone in patients with advanced urothelial carcinoma.

Srikala sridharDepartment of medicineUniversity of torontoCancers symposiumCancer clinical research unitPrincess margaret cancer centerGenitourinary medical oncologistsMedical advisory boardBladder cancer canadaNew england journalPost hoc analysis from the phase 3 javelin bladder 100 trialFirst line maintenance avelumabPatients with advanced urothelial carcinomaThe university of toronto

Merck: New Analyses Reinforce Survival Benefit of BAVENCIO First-Line Maintenance Treatment in Patients With Advanced Urothelial Carcinoma

Not intended for UK-based media Long-term follow-up of the Phase III JAVELIN Bladder 100 study demonstrated median overall survival from start of chemotherapy of 29.7 months among patients receiving

United statesSrikala sridharAmerican society of clinical oncologyMerck pressEuropean commissionDrug administrationPrincess margaret cancer centreMerck kgaMerck kgaaAmerican cancer societyUnited kingdom basedClinical oncologyGenitourinary cancers symposiumSenior vice president headMedical unit oncologySession details

New Analyses Reinforce Survival Benefit of BAVENCIO First-Line Maintenance Treatment in Patients With Advanced Urothelial Carcinoma

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced findings of a new analysis of long-term follow-up data from the Phase III JAVELIN Bladder 100 trial.

United statesSrikala sridharAmerican society of clinical oncologyMerck pressEuropean commissionDrug administrationPrincess margaret cancer centreMerck kgaMerck kgaaAmerican cancer societyUnited kingdom basedClinical oncologyGenitourinary cancers symposiumSenior vice presidentMedical unit oncologySession details

Mashup Media and The Uromigos Launch First Live Conference in GU Oncology Space

Manalapan, N.J. (PRWEB) August 29, 2022 Mashup Media, LLC, in partnership with Drs. Thomas Powles and Brian Rini of The Uromigos, is pleased to announce

Michael morrisJonathan rosenberg srikala sridharAxel bexDavid mcdermottPetros grivasMatthew galskyBrian riniCourtney leonardNick jamesShilpa guptaNeeraj agarwalSumanta palDaniel georgeThomas powlesRana mckayMashup media